BRIEF-Amgen UK Says Imdylltra Gets Conditional Nod for 3rd-Line Extensive-Stage SCLC
ReutersJan 6, 2025 9:33 AM
Jan 6 (Reuters) - Amgen UK:
IMDYLLTRA GRANTED CONDITIONAL MARKETING AUTHORISATION FOR THIRD-LINE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER IN UK
Source text: ID:nBw6c766Ja
Further company coverage: AMGN.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Related Articles
Stocks Themes that can Make Big Moves at The Consumer Electronics Show (CES) 2025
Historically, CES was mainly for tech enthusiasts. However, recently it has been attracting a lot of attention from investors wanting to see how consumer electronic firms will be able to navigate the AI wave to boost their sales.TradingKey
16 hours ago
Does Qualcomm (QCOM) Have the Potential to be the Next Nvidia?
Source: TradingView Too Many Uncertainties for QCOM to Go Up but Limited Downside, HOLD In 2024, Qualcomm (QCOM) stock price went up just 10% - tepidTradingKey
22 hours ago
Weekly Market Outlook: U.S. December Jobs Data in Focus and CES 2025 Kicks Off
TradingKey – This week, key events include the U.S. December nonfarm payroll report, the Fed’s December meeting minutes, and CES 2025, the world’s largest tech expo, running January 7–10 in Las Vegas. Companies like NVIDIA, AMD, and Samsung are set to unveil major innovations.TradingKey
23 hours ago
